Cipla Propels Lung Leadership Plans, Reimagines Operating Models

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

MT1906_human-lungs_98111591_1200.jpg
Cipla builds global respiratory franchise • Source: Shutterstock

Cipla Ltd. did not share a great deal of detail on the much publicized licensing pact with Gilead Sciences Inc. for remdesivir at the firm’s fourth-quarter 2020 earnings call but the management drew attention to the momentum in the respiratory segment, where the firm has now filed an ANDA for a generic version of GlaxoSmithKline PLC’s Advair Diskus (salmeterol/fluticasone) in the US.

Cipla, which aspires for lung leadership across markets, also highlighted the unlocking of its respiratory franchise in the US with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip